Influencing Factors on the Oncuria™ Urinalysis Assay: An Experimental Model
Open Access
- 3 June 2021
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 11 (6) , 1023
Abstract
Background: The Oncuria™ urine test for the detection of bladder cancer measures a multiplex protein signature. In this study, we investigated the influence of urinary cellularity, protein, and hematuria on the performance of the Oncuria™ test in an ex vivo experimental model. Materials and Methods: Pooled urine from healthy subjects was spiked with cultured benign (UROtsa) or malignant cells (T24), cellular proteins, or whole blood. The resulting samples were analyzed using the Oncuria™ test following the manufacturer’s instructions. Results: Urine samples obtained from healthy subjects were negative for bladder cancer by Oncuria™ test criteria. The majority of the manipulated conditions did not result in a false-positive test. The addition of whole blood (high concentration) did result in a false-positive result, but this was abrogated by sample centrifugation prior to analysis. The addition of cellular proteins (high concentration) resulted in a positive Oncuria™ test, and this was unaffected by pre-analysis sample centrifugation. Conclusions: The Oncuria™ multiplex test performed well in the ex vivo experimental model and shows promise for clinical application. The identification of patients who require additional clinical evaluation could reduce the need to subject patients who do not have bladder cancer to frequent, uncomfortable and expensive cystoscopic examinations, thus benefiting both patients and the healthcare system.Keywords
Funding Information
- National Cancer Institute (R01 CA1988887, R01 CA206584)
This publication has 42 references indexed in Scilit:
- Investigation of CCL18 and A1AT as potential urinary biomarkers for bladder cancer detectionBMC Urology, 2013
- A Multi-Analyte Assay for the Non-Invasive Detection of Bladder CancerPLOS ONE, 2012
- Influencing factors on the NMP-22 urine assay: an experimental modelBMC Urology, 2012
- Urinary Glycoprotein Biomarker Discovery for Bladder Cancer Detection Using LC/MS-MS and Label-Free QuantificationClinical Cancer Research, 2011
- Bladder Cancer–Associated Gene Expression Signatures Identified by Profiling of Exfoliated UrotheliaCancer Epidemiology, Biomarkers & Prevention, 2009
- UroVysion FISH test for detecting urothelial cancers: Meta-analysis of diagnostic accuracy and comparison with urinary cytology testingUrologic Oncology: Seminars and Original Investigations, 2008
- Bladder Cancer Associated Glycoprotein Signatures Revealed by Urinary Proteomic ProfilingJournal of Proteome Research, 2007
- Urine Markers for Bladder Cancer Surveillance: A Systematic ReviewEuropean Urology, 2005
- Use of a New Tumor Marker, Urinary NMP22, in the Detection of Occult or Rapidly Recurring Transitional Cell Carcinoma of the Urinary Tract Following Surgical TreatmentJournal of Urology, 1996
- Use of a New Tumor Marker, Urinary NMP22, in the Detection of Occult or Rapidly Recurring Transitional Cell Carcinoma of the Urinary Tract Following Surgical TreatmentJournal of Urology, 1996